<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002176</url>
  </required_header>
  <id_info>
    <org_study_id>244C</org_study_id>
    <secondary_id>AI455-062</secondary_id>
    <nct_id>NCT00002176</nct_id>
  </id_info>
  <brief_title>A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection</brief_title>
  <official_title>A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To assess the magnitude and duration of the antiviral activity in plasma and the incidence
      and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety
      and tolerability of this combination therapy and the magnitude and duration of the effect of
      this therapy over CD4 cell counts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">March 2000</completion_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Documented HIV infection.

          -  CD4 count &gt; 500 cells/mm3.

          -  No HIV-associated symptoms.

          -  Written, informed consent from parent or legal guardian for patients &lt; 18 years old.

          -  Availability for follow-up for at least 96 weeks.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions and symptoms are excluded:

          -  Presence of a newly diagnosed AIDS-defining opportunistic infection requiring acute
             therapy at the time of enrollment.

          -  Intractable diarrhea.

          -  Signs and symptoms of bilateral peripheral neuropathy &gt;= Grade 2.

          -  Inability to tolerate oral medication.

          -  Hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue.

        Patients with the following prior conditions are excluded:

        History of acute or chronic pancreatitis. 1. Use of potent neurotoxic drugs is not
        permitted.

          -  No other anti-HIV therapy allowed.

          -  Nelfinavir should not be administered concurrently with rifampin or rifabutin,
             terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam
             (Halcion), and midazolam (Versed).

             1. Any prior antiretroviral therapy.

          -  Prior vaccination with a candidate HIV therapeutic vaccine.

          -  Previous therapy with agents with significant systemic myelosuppressive, neurotoxic,
             pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or
             the expected need for such therapy at the time of enrollment.

          -  Previous therapy with rifampin or rifabutin, terfenadine (Seldane), astemizole
             (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed) within
             14 days prior to study entry or at any time while on study.

        Active alcohol or substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>. ., .</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of California at San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>April 13, 2011</last_update_submitted>
  <last_update_submitted_qc>April 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <keyword>Pilot Projects</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Stavudine</keyword>
  <keyword>Hydroxyurea</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

